Regenerative medicine specialist CollPlant has partnered with BICO firm CELLINK in an effort to ramp up its production of 3D bioprinted breast implants. 

Currently undergoing preclinical trials, CollPlant’s bioprinted grafts are designed to degrade over time and be replaced by native tissues, in a treatment that could prove much safer than traditional augmentation procedures. In an effort to scale the production of these grafts, the firm has now begun working with CELLINK, in a partnership with the potential to unlock a market it values at $2.8 billion. 

Read the full article at